Einzeltreffer — DigiBib

Objective: The COVID-19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost-effectiveness evidence of economic evaluation of COVID-19 vaccination strategies to provide evidence supporting the usage of COVID-19 vaccination, especially where the supply of COVID-19 vaccine is limited.

Methods: A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442).

Results: Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID-19 vaccination and booster vaccination were cost-effective or cost-saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost-effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost-effective.

Conclusions: COVID-19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID-19 vaccination is needed.

Titel:	Cost-effectiveness of COVID-19 vaccination: A systematic review.
Autor/in / Beteiligte Person:	Fu, Y ; Zhao, J ; Han, P ; Zhang, J ; Wang, Q ; Wei, X ; Yang, L ; Ren, T ; Zhan, S ; Li, L
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of evidence-based medicine, Jg. 16 (2023-06-01), Heft 2, S. 152-165
Veröffentlichung:	Oxford : Wiley-Blackwell, 2023
Medientyp:	academicJournal
ISSN:	1756-5391 (electronic)
DOI:	10.1111/jebm.12525
Schlagwort:	Humans Aged Cost-Benefit Analysis Vaccination COVID-19 Vaccines therapeutic use COVID-19 prevention & control
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Systematic Review; Journal Article Language: English [J Evid Based Med] 2023 Jun; Vol. 16 (2), pp. 152-165. <i>Date of Electronic Publication: </i>2023 Apr 26. MeSH Terms: COVID-19 Vaccines* / therapeutic use ; COVID-19* / prevention & control ; Humans ; Aged ; Cost-Benefit Analysis ; Vaccination References: Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8), 1212-1217. ; Keogh-Brown MR, Jensen HT, Edmunds WJ, Smith RD. The impact of Covid-19, associated behaviours and policies on the UK economy: a computable general equilibrium model. SSM-Population Health. 2020;12:100651. ; John D, Narassima MS, Menon J, Rajesh JG, Banerjee A. Estimation of the economic burden of COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a model-based analysis. BMJ Open. 2021;11(8), e049619. ; Jin H, Wang H, Li X, et al. Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study. Bull World Health Organ. 2021;99(2), 112-124. ; Organization WH. WHO Coronavirus (COVID-19) Dashboard https://covid19.who.int/2022 [accessed 2022 August 29]. ; Organization WH. COVID-19 vaccine tracker and landscape https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines2022 [accessed 2022 July 6]. ; Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: a Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1), 10-31. ; Rezapour A, Souresrafil A, Peighambari MM, Heidarali M, Tashakori-Miyanroudi M. Economic evaluation of programs against COVID-19: a systematic review. Int J Surg (Lond, Engl). 2021;85:10-18. ; Kirson N, Swallow E, Lu J, et al. The societal economic value of COVID-19 vaccines in the United States. J Med Econ. 2022;25(1), 119-128. ; Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis. 2022;119:87-94. ; Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39(7), 1157-1164. ; Padula WV, Malaviya S, Reid NM, et al. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021;24(1), 1060-1069. ; Bartsch SM, O'Shea KJ, Wedlock PT, et al. The benefits of vaccinating with the first available COVID-19 coronavirus vaccine. Am J Prev Med. 2021;60(5), 605-613. ; Shaker M, Abrams EM, Greenhawt M. A cost-effectiveness evaluation of hospitalizations, fatalities, and economic outcomes associated with universal versus anaphylaxis risk-stratified COVID-19 vaccination strategies. J Allerg Clini Immunol: In Pract. 2021;9(7), 2658-2668.e3. ; Bartsch SM, Wedlock PT, O'Shea KJ, et al. Lives and costs saved by expanding and expediting coronavirus disease 2019 vaccination. J Infect Dis. 2021;224(6), 938-948. ; Marco-Franco JE, Pita-Barros P, González-De-julián S, Sabat I, Vivas-Consuelo D. Simplified mathematical modelling of uncertainty: cost-effectiveness of COVID-19 vaccines in Spain. Mathematics. 2021;9(5), 566. ; Nurchis MC, Lontano A, Pascucci D, et al. COVID-19 vaccination campaign among the health workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a cost-benefit analysis. Int J Environ Res Public Health. 2022;19(13), 7848. ; Kirwin E, Rafferty E, Harback K, Round J, McCabe C. A net benefit approach for the optimal allocation of a COVID-19 vaccine. Pharmacoeconomics. 2021;39(9), 1059-1073. ; Debrabant K, Grønbaek L, Kronborg C. The Cost-effectiveness of a COVID-19 vaccine in a Danish context. Clin Drug Invest. 2021;41(11), 975-988. ; Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M. Centre for the Mathematical Modelling of Infectious Diseases C-wg. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;21(7), 962-974. ; López F, Català M, Prats C, et al. A cost-benefit analysis of COVID-19 vaccination in Catalonia. Vaccines. 2022;10(1), 59. ; Wang WC, Fann JCY, Chang RE, et al. Economic evaluation for mass vaccination against COVID-19. J Formos Med Assoc. 2021;120:S95-S105. ; Xiong X, Li J, Huang B, et al. Economic value of vaccines to address the COVID-19 pandemic in Hong Kong: a cost-effectiveness analysis. Vaccines. 2022;10(4), 495. ; Fu Y, Zhao J, Wei X, et al. Effectiveness and cost-effectiveness of inactivated vaccine to address COVID-19 pandemic in China: evidence from randomized control trials and real-world studies. Front Public Health. 2022;10:917732. ; Fernandes RRA, Santos MdS, Magliano CAdS, et al. Cost utility of vaccination against COVID-19 in Brazil. Value Health Reg Issues. 2022;31:18-24. ; Siqueira PG, Duarte HO, Moura MDC. Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: coronavac vs. Astrazeneca vs Pfizer. Vaccine. 2022;19:19. ; Hagens A, Inkaya AC, Yildirak K, et al. COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. Vaccines. 2021;9(4), 399. ; Vaezi A, Meysamie A. COVID-19 vaccines cost-effectiveness analysis: a scenario for Iran. Vaccines. 2022;10(1), 37. ; Pearson CAB, Bozzani F, Procter SR, et al. COVID-19 vaccination in Sindh Province, Pakistan: a modelling study of health impact and cost-effectiveness. PLoS Med. 2021;18(10), e1003815. ; Morales-Zamora G, Espinosa O, Puertas E, et al. Cost-effectiveness analysis of strategies of COVID-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan. Value Health Reg Issues. 2022;31:101-110. ; Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nat Commun. 2021;12(1), 6238. ; Suphanchaimat R, Tuangratananon T, Rajatanavin N, Phaiyarom M, Jaruwanno W, Uansri S. Prioritization of the target population for coronavirus disease 2019 (COVID-19) vaccination program in Thailand. Int J Environ Res Public Health. 2021;18(20), 14. ; Volodymyrovych TY, Ivanovich SV, Tetiana K, Yaroslavovych TB. Pharmaco economics analysis of COVID-19 vaccines in Ukraine. J Pharmaceut Res Int. 2021;33(32A), 140-147. ; Orlewska K, Wierzba W, Sliwczynski A. Cost-effectiveness analysis of COVID-19 vaccination in Poland. Arch Med Sci. 2022;18(4), 1021-1030. ; Orangi S, Ojal J, Brand SPC, et al. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya. BMJ Global Health. 2022;7:e009430. ; Jiang Y, Cai D, Shi S. Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: a modeling study. Infect Dis Model. 2022;7(1), 109-121. ; Rezapour A, Souresrafil A, Peighambari MM, Heidarali M, Tashakori-Miyanroudi M. Economic evaluation of programs against COVID-19: a systematic review. Int J Surg. 2021;85:10-18. ; Zhou L, Yan W, Li S, et al. Cost-effectiveness of interventions for the prevention and control of COVID-19: systematic review of 85 modelling studies. J Glob Health. 2022;12:05022. ; Ramachandran R, Dhodapkar M, Ross JS, Schwartz JL. Future of covid-19 vaccine pricing: lessons from influenza. BMJ. 2021;373:n1467. ; Belayachi J, Obtel M, Razine R, Abouqal R. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco. PLoS One. 2022 Dec 7;17(12), e0278546. ; Glöckner S, Hornung F, Baier M, et al. Robust neutralizing antibody levels detected after either SARS-CoV-2 vaccination or one year after infection. Viruses. 2021;13(10), 2003. ; Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12), 2108-2110. ; Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4), 483-495. ; Abbasi J. Studies suggest COVID-19 vaccine boosters save lives. JAMA. 2022;327(2), 115. ; Guo W, Duan K, Zhang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine. 2021;38:101010. ; Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv. 2021. 2021.07.23.21261026. ; Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385(17), 1627-1629. ; Saban M, Myers V, Wilf-Miron R. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: the Israeli case. Prev Med. 2022;154:106890. ; Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15), 1393-1400. ; Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316), 2093-2100. Grant Information: 72174010 National Natural Science Foundation of China; M22033 Natural Science Foundation of Beijing Municipality; 2021-1G-4091 Capital Health Research and Development of Special Fund Contributed Indexing: Keywords: COVID-19; cost; economic evaluation; effectiveness; vaccination Substance Nomenclature: 0 (COVID-19 Vaccines) Entry Date(s): Date Created: 20230515 Date Completed: 20230712 Latest Revision: 20230718 Update Code: 20240514

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Cost-effectiveness of COVID-19 vaccination: A systematic review.